Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
• Cholesterol-Lowering Program:
– Preclinical dose formulation work finalised
– Remaining safety and pharmacology studies to be completed end of April
– Phase I/IIa first-in-human study to start early 2H CY2023
– Mr Seth Gordon, former pivotal member of the Lipitor® marketing team at Pfizer,
appointed as Principal Consultant to advise on program strategy and asset
development
• Brain Injury Program:
– Preclinical in vitro safety and toxicology studies well advanced, in vivo studies to follow
– Phase I first-in-human study to commence 1H CY2023
– Results from preclinical stroke model study expected mid Q2-CY2023
– International patent search confirms Nyrada’s TRPC channel blocker is “novel and
inventive”, indicating that our PCT patent is likely to be granted
• Cash balance of $6.6M, well-placed to pursue clinical development in CY2023